Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Novel Elecsys Growth Differentiation Factor-15 (GDF-15) Assay Discovered for Cancer Treatment

Elecsys® GDF-15 assay discovered as a Companion Diagnostic (CDx) for the treatment of cancer. It helps in finding patients suitable for innovative treatment addressing unintentional weight loss in cancer patients.

Elecsys GDF-15 a quantitative serologic which uses the format of sandwich test for the detection of GDF-15 in human serum. This helps in identifying solid tumours for treatment with PF-06946860 in patients 18 years of age and older.

Cachexia results in metabolic disorder which arises with several chronic diseases such as cancer, heart failure, Chronic Obstructive Pulmonary Disease (COPD), and Chronic Kidney Disease (CKD). It is a major complication of cancer affecting more than half of cancer patients worldwide.

GDF-15 is associated with cachexia in cancer patients, leading to successful cachexia treatment with better outcomes globally.

U.S. Food and Drug Administration (FDA) grants Breakthrough Device Designation to Elecsys® GDF-15 assay as a Companion Diagnostic (CDx) in cancer treatment.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024